

IUSTI EUROPE Webinar 21

TO DoxyPEP OR NOT TO DoxyPEP

Dr. Otilia Mardh

Bio:

Otilia Mardh is a medical epidemiologist, scientific officer at ECDC with long term contribution to the scientific advice, surveillance, epidemic intelligence and response activities in the areas of STI, HIV and hepatitis at EU/EEA level. In the last three years, she coordinated the update of joint ECDC and EMCDDA guidance for prevention of infections among people who inject drugs and the development of related technical reports. Additional recent work includes an analysis of epidemiological trends of bacterial STI under surveillance in EU/EEA for EACS 2021 and the related STI BMJ publication, a descriptive analysis of mortality from liver diseases attributable to hepatitis B/C. Permanent work includes communication with the EU/EEA STI Network directly or through the STI Network Coordination Committee and EpiPulse STI platform and contributions to the ECDC risk assessment in relation to emerging infections and public health threats. She is representing ECDC in the IUSTI Europe STI Guidelines Project Editorial Board.

Prof. Jean Michael Molina

Bio:

Jean-Michel Molina is Professor of Infectious Diseases at the University of Paris, and Head of the Infectious Diseases Department at the Saint-Louis and Lariboisière Hospitals in Paris, France. The Department of Infectious Diseases is mainly involved in the care of immunocompromised patients, patients with HIV infection, bone marrow and renal transplant recipients, and patients with haematological malignancies and cancers. Professor Molina's primary clinical research interest focuses on HIV infection, initially the treatment of AIDS-related opportunistic infections, and then the treatment of HIV infection. He has been involved in a number of studies assessing new drugs or new strategies for the treatment of HIV infection. A cohort of more than 6,000 patients with HIV infection is followed in his department. He is also a member of the French National Institute of Health and Medical Research (INSERM) U944 team at the Saint-Louis Hospital investigating cell biology of viral infections. He has authored many papers in a wide variety of scientific journals, including Clinical Infectious Diseases, the Journal of Infectious Diseases, the New England Journal of Medicine, the Lancet and AIDS. Professor Molina is also involved in the French National Agency for AIDS Research (ANRS), where he chaired the clinical trial group for the last 12 years. More recently, Professor Molina has broadened his field of interest to the prevention of HIV infection with antiretrovirals and has led the ANRS IPERGAY pre-exposure prophylaxis (PrEP) trial in men who have sex with men. A cohort of more than 3,500 people on PrEP is followed in his unit, and a new ANRS PrEP study (ANRS Prevenir) is implemented in the Paris region to contain the HIV epidemic among gay men.

Dr. Chris Kenyon

Bio:

Chris Kenyon is an academic researcher from Institute of Tropical Medicine Antwerp. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 27,

co-authored 258 publications receiving 2938 citations. Previous affiliations of Chris Kenyon include University of Antwerp & Lloyds Banking Group.

Prof. Henry de Vries

Bio:

Henry de Vries (1967) is dermatologist-venereologist with expertise in skin infections, especially sexually transmitted infections and tropical skin diseases. In 2010 he was appointed Professor of skin infections at the University of Amsterdam. He is currently employed as a trainer of dermatology residents at the Public Health Service Amsterdam STI outpatient clinic, the largest outpatient clinic in the Netherlands with around 50,000 new consultations per year. In cooperation with the public health laboratory and research department of infectious diseases of the cluster PHS Amsterdam, he leads a research group including 15 PhD students. He also works at the Department of Dermatology at the Amsterdam University Medical Centres, the Netherlands, where every Monday he supervises the outpatient clinic for infectious diseases of the skin especially tropical skin diseases such as leishmaniasis and leprosy. De Vries is co-author of 270 registered PubMed publications. He is lead author for the IUSTI European guidelines on lymphogranuloma venereum and STI related proctitis.

Dr. Andrew Winter

Bio:

Dr Winter was appointed Consultant in Sexual Health and HIV in Glasgow, UK in 1999 after completing a PhD in Infection at Birmingham University and higher medical training in the Midlands. Dr Winter's main interest is in digital health leadership: he led adoption of the national sexual health system in Scotland, was appointed as clinical eHealth lead in NHS Greater Glasgow and Clyde in 2015, and in 2020 became Vice-Chair of the Scottish Health and Care Digital Network. He was in the first cohort of the UK's NHS Digital Academy and is a Fellow of the Faculty of Clinical Informatics. His clinical interests are in HIV care and STI diagnostic testing. He is a member of the European IUSTI Guidelines Group, UK Country Representative for IUSTI Europe and chairs IUSTI Europe's communication group.

Prof. Fiona Lyons

Bio:

Prof. Fiona Lyons is a consultant in GU/HIV Medicine at the GUIDE clinic, St. James's Hospital and Clinical Professor at the School of Medicine, Trinity College, Dublin. Fiona took up her consultant post in 2007. Between October 2015 and September 2018 she was national clinical lead in sexual health, working in the National Sexual Health and Crisis Pregnancy Programme on implementation of Ireland's first national sexual health strategy. During her time as Clinical Lead she oversaw the development of National Standards, Eligibility Criteria and Guidelines for HIV PrEP and the implementation of Ireland's HIV PrEP programme in 2019. Her special interests include HIV infection in women, pregnancy, HIV prevention and new models of STI care delivery. Fiona resumed her role as national clinical lead at the National Sexual Health and Crisis Pregnancy Programme in September 2021 for a five year tenure to continue work on the clinical actions in the sexual health strategy.